The effect of the long term aspirin administration on the progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse

Thrombosis Research

Volumn 125, Issue 3, 2010, Pages 246-252

  Yamamoto, Y ^a   Yamashita, T ^a   Kitagawa, F ^a   Sakamoto, K ^a   Giddings, J C ^b   Yamamoto, J ^a  

^a Faculty of Nutrition   (Japan)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Aspirin; Atherosclerosis; Endothelial function; Nitric oxide

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN RECEPTOR; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN F1 ALPHA; THROMBOXANE B2;

ANIMAL EXPERIMENT; AORTA; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLEEDING TIME; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; ENDOTHELIUM CELL; LONG TERM CARE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETYLCHOLINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AORTA; APOLIPOPROTEINS E; ASPIRIN; ATHEROSCLEROSIS; DIET, ATHEROGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HOMOZYGOTE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; TIME FACTORS;

EID: 77049107077     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.11.008     Document Type: Article

References (37)

1. Bertrand M.E. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 20 10 (2004) 1559-1569
2. Napoli C., Lerman L.O., de Nigris F., Gossl M., Balestrieri M.L., and Lerman A. Rethinking primary prevention of atherosclerosis-related diseases. Circulation 114 23 (2006) 2517-2527
3. Patel T.N., Shishehbor M.H., and Bhatt D.L. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 28 6 (2007) 664-672
4. Kim I., Moon S.O., Kim S.H., Kim H.J., Koh Y.S., and Koh G.Y. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276 10 (2001) 7614-7620
5. Gasparyan A.Y., Watson T., and Lip G.Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51 19 (2008) 1829-1843
6. Yamashita T., Oda E., Sano T., Ijiru Y., Giddings J.C., and Yamamoto J. Varying the ratio of dietary n-6/n-3 polyunsaturated fatty acid alters the tendency to thrombosis and progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse. Thromb Res 116 5 (2005) 393-401
7. Yamashita T., Shoge M., Oda E., Yamamoto Y., Giddings J.C., Kashiwagi S., Suematsu M., and Yamamoto J. The free-radical scavenger, edaravone, augments NO release from vascular cells and platelets after laser-induced, acute endothelial injury in vivo. Platelets 17 3 (2006) 201-206
8. Zhang X. Real time and in vivo monitoring of nitric oxide by electrochemical sensors-from dream to reality. Front Biosci 9 (2004) 3434-3446
9. Teraki Y., Moriya N., and Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol 145 3 (1994) 550-560
10. Weiss E.J., Hamilton J.R., Lease K.E., and Coughlin S.R. Protection against thrombosis in mice lacking PAR3. Blood 100 9 (2002) 3240-3244
11. Clarke R.J., Mayo G., Price P., and FitzGerald G.A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325 16 (1991) 1137-1141
12. Witting P.K., Pettersson K., Ostlund-Lindqvist A.M., Westerlund C., Eriksson A.W., and Stocker R. Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice. FASEB J 13 6 (1999) 667-675
13. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 2 (1999) 115-126
14. Reape T.J., and Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 147 2 (1999) 213-225
15. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., and Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2 2 (1998) 275-281
16. Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., Page M., Kaltschmidt C., Baeuerle P.A., and Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97 7 (1996) 1715-1722
17. Hofmann M.A., Lalla E., Lu Y., Gleason M.R., Wolf B.M., Tanji N., Ferran Jr. L.J., Kohl B., Rao V., Kisiel W., Stern D.M., and Schmidt A.M. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107 6 (2001) 675-683
18. Vane J.R., and Botting R.M. The mechanism of action of aspirin. Thromb Res 110 5-6 (2003) 255-258
19. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., and Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95 22 (1998) 13313-13318
20. Kyrle P.A., Minar E., Brenner B., Eichler H.G., Heistinger M., Marosi L., and Lechner K. Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis-effect of low-dose aspirin. Thromb Haemost 61 3 (1989) 374-377
21. Babaev V.R., Ding L., Reese J., Morrow J.D., Breyer M.D., Dey S.K., Fazio S., and Linton M.F. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113 1 (2006) 108-117
22. Deanfield J.E., Halcox J.P., and Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 10 (2007) 1285-1295
23. Coats P., Johnston F., MacDonald J., McMurray J.J., and Hillier C. Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation 103 12 (2001) 1702-1708
24. Katz S.D., Schwarz M., Yuen J., and LeJemtel T.H. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 88 1 (1993) 55-61
25. Forstermann U., Mugge A., Alheid U., Haverich A., and Frolich J.C. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 62 2 (1988) 185-190
26. Prasad K., and Lee P. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther 8 1 (2003) 61-69
27. Exner M., Hermann M., Hofbauer R., Kapiotis S., Speiser W., Held I., Seelos C., and Gmeiner B.M. The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein. FEBS Lett 470 1 (2000) 47-50
28. Hsu C.S., and Li Y. Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention. Biochem Biophys Res Commun 293 2 (2002) 705-709
29. Wijendran V., and Hayes K.C. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Annu Rev Nutr 24 (2004) 597-615
30. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 4 (2004) 1381-1478
31. Maree A.O., and Fitzgerald D.J. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115 16 (2007) 2196-2207
32. Hart R.G., and Harrison M.J. Aspirin wars: the optimal dose of aspirin prevent stroke. Stroke 27 4 (1996) 585-587
33. Campbell C.L., Smyth S., Montalescot G., and Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 18 (2007) 2018-2024
34. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., Jinnouchi H., Sugiyama S., and Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 18 (2008) 2134-2141
35. Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K., Hochman J.S., Krumholz H.M., Lamas G.A., Mullany C.J., Pearle D.L., Sloan M.A., Smith Jr. S.C., Anbe D.T., Kushner F.G., Ornato J.P., Jacobs A.K., Adams C.D., Anderson J.L., Buller C.E., Creager M.A., Ettinger S.M., Halperin J.L., Hunt S.A., Lytle B.W., Nishimura R., Page R.L., Riegel B., Tarkington L.G., and Yancy C.W. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117 2 (2008) 296-329
36. Patrignani P., Filabozzi P., and Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69 6 (1982) 1366-1372
37. Ferrell M., Fuster V., Gold H.K., and Chesebro J.H. A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis. Circulation 85 4 (1992) 1630-1631